3D model (JSmol)
|Molar mass||269.40 g/mol|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
2C-T-17 or 2,5-dimethoxy-4-(β-secbutylthio)phenethylamine is a psychedelic phenethylamine of the 2C family. It was presumably first synthesized by Alexander Shulgin and reported in his book PiHKAL (Phenethylamines i Have Known And Loved).
2C-T-17 is the 2 carbon homologue of Aleph-17, which has never been synthesized. The full chemical name is 2-[4-(2-butyl thio)-2,5-dimethoxy phenyl]ethanamine. The drug has structural properties similar to drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-8.
The dosage range of 2C-T-17 is typically 60-100 mg and its duration is approximately 10–15 hours according to Shulgin. 2C-T-17 has highly psychedelic effects on thinking, but produces few to no visuals.
The mechanism that produces 2C-T-17's hallucinogenic and entheogenic effects has not been specifically established, however it is most likely to result from action as a 5-HT2A serotonin receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.
The toxicity of 2C-T-17 is not well documented. 2C-T-17 is much less potent than 2C-T-7, but it may be expected that at very high doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.
As of October 31st, 2016; 2C-T-17 is a controlled substance (Schedule III) in Canada. http://gazette.gc.ca/rp-pr/p2/2016/2016-05-04/html/sor-dors72-eng.php
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.